Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

Background Non-alcoholic steatohepatitis (NASH) is a common type of chronic liver disease that can lead to cirrhosis. Obeticholic acid, a farnesoid X receptor agonist, has been shown to improve the histological features of NASH. Here we report results from a planned interim analysis of an ongoing, phase 3 study of obeticholic acid for NASH. Methods In this multicentre, randomised, double-blind, placebo-controlled study, adult patients with definite NASH,non-alcoholic fatty liver disease (NAFLD) activity score of at least 4, and fibrosis stages F2–F3, or F1 with at least oneaccompanying comorbidity, were randomly assigned using an interactive web response system in a 1:1:1 ratio to receive oral placebo, obeticholic acid 10 mg, or obeticholic acid 25 mg daily. Patients were excluded if cirrhosis, other chronic liver disease, elevated alcohol consumption, or confounding conditions were present. The primary endpointsfor the month-18 interim analysis were fibrosis improvement (≥1 stage) with no worsening of NASH, or NASH resolution with no worsening of fibrosis, with the study considered successful if either primary endpoint was met. Primary analyses were done by intention to treat, in patients with fibrosis stage F2–F3 who received at least one dose of treatment and reached, or would have reached, the month 18 visit by the prespecified interim analysis cutoff date. The study also evaluated other histological and biochemical markers of NASH and fibrosis, and safety. This study is ongoing, and registered with ClinicalTrials.gov, NCT02548351, and EudraCT, 20150-025601-6. Findings Between Dec 9, 2015, and Oct 26, 2018, 1968 patients with stage F1–F3 fibrosis were enrolled and received at least one dose of study treatment; 931 patients with stage F2–F3 fibrosis were included in the primary analysis (311 in the placebo group, 312 in the obeticholic acid 10 mg group, and 308 in the obeticholic acid 25 mg group). The fibrosis improvement endpoint was achieved by 37 (12%) patients in the placebo group, 55 (18%) in the obeticholic acid 10 mg group (p=0·045), and 71 (23%) in the obeticholic acid 25 mg group (p=0·0002). The NASH resolution endpoint was not met (25 [8%] patients in the placebo group, 35 [11%] in the obeticholic acid 10 mg group [p=0·18], and 36 [12%] in the obeticholic acid 25 mg group [p=0·13]). In the safety population (1968 patients with fibrosis stages F1–F3), the most common adverse event was pruritus (123 [19%] in the placebo group, 183 [28%] in the obeticholic acid 10 mg group, and 336 [51%] in the obeticholic acid 25 mg group); incidence was generally mild to moderate in severity. The overall safety profile was similar to that in previous studies, and incidence of serious adverse events was similar across treatment groups (75 [11%] patients in the placebo group, 72 [11%] in the obeticholic acid 10 mg group, and 93 [14%] in the obeticholic acid 25 mg group). Interpretation Obeticholic acid 25 mg significantly improved fibrosis and key components of NASH disease activity among patients with NASH. The results from this planned interim analysis show clinically significant histological improvement that is reasonably likely to predict clinical benefit. This study is ongoing to assess clinical outcomes

Lancet

BACKGROUND: In 2015, the second cycle of the CONCORD programme established global surveillance of cancer survival as a metric of the effectiveness of health systems and to inform global policy on cancer control. CONCORD-3 updates the worldwide surveillance of cancer survival to 2014. METHODS: CONCORD-3 includes individual records for 37.5 million patients diagnosed with cancer during the 15-year period 2000-14. Data were provided by 322 population-based cancer registries in 71 countries and territories, 47 of which provided data with 100% population coverage. The study includes 18 cancers or groups of cancers: oesophagus, stomach, colon, rectum, liver, pancreas, lung, breast (women), cervix, ovary, prostate, and melanoma of the skin in adults, and brain tumours, leukaemias, and lymphomas in both adults and children. Standardised quality control procedures were applied; errors were rectified by the registry concerned. We estimated 5-year net survival. Estimates were age-standardised with the International Cancer Survival Standard weights. FINDINGS: For most cancers, 5-year net survival remains among the highest in the world in the USA and Canada, in Australia and New Zealand, and in Finland, Iceland, Norway, and Sweden. For many cancers, Denmark is closing the survival gap with the other Nordic countries. Survival trends are generally increasing, even for some of the more lethal cancers: in some countries, survival has increased by up to 5% for cancers of the liver, pancreas, and lung. For women diagnosed during 2010-14, 5-year survival for breast cancer is now 89.5% in Australia and 90.2% in the USA, but international differences remain very wide, with levels as low as 66.1% in India. For gastrointestinal cancers, the highest levels of 5-year survival are seen in southeast Asia: in South Korea for cancers of the stomach (68.9%), colon (71.8%), and rectum (71.1%); in Japan for oesophageal cancer (36.0%); and in Taiwan for liver cancer (27.9%). By contrast, in the same world region, survival is generally lower than elsewhere for melanoma of the skin (59.9% in South Korea, 52.1% in Taiwan, and 49.6% in China), and for both lymphoid malignancies (52.5%, 50.5%, and 38.3%) and myeloid malignancies (45.9%, 33.4%, and 24.8%). For children diagnosed during 2010-14, 5-year survival for acute lymphoblastic leukaemia ranged from 49.8% in Ecuador to 95.2% in Finland. 5-year survival from brain tumours in children is higher than for adults but the global range is very wide (from 28.9% in Brazil to nearly 80% in Sweden and Denmark). INTERPRETATION: The CONCORD programme enables timely comparisons of the overall effectiveness of health systems in providing care for 18 cancers that collectively represent 75% of all cancers diagnosed worldwide every year. It contributes to the evidence base for global policy on cancer control. Since 2017, the Organisation for Economic Co-operation and Development has used findings from the CONCORD programme as the official benchmark of cancer survival, among their indicators of the quality of health care in 48 countries worldwide. Governments must recognise population-based cancer registries as key policy tools that can be used to evaluate both the impact of cancer prevention strategies and the effectiveness of health systems for all patients diagnosed with cancer. FUNDING: American Cancer Society; Centers for Disease Control and Prevention; Swiss Re; Swiss Cancer Research foundation; Swiss Cancer League; Institut National du Cancer; La Ligue Contre le Cancer; Rossy Family Foundation; US National Cancer Institute; and the Susan G Komen Foundation

Involvement of the Posterior Intracranial Circulation in Giant Cell Arteritis

Giant cell arteritis (GCA) is the most common primary vasculitis affecting the elderly population. GCA preferentially involves the extracranial branches of the carotid artery with sparing of intracranial vessels (Wilkinson and Russell,1972). Occlusive vasculitis or embolization of inflammatory thrombus can result in ischemic stroke, found in approximately 2-4% of GCA patients. One series reported an incidence of 2.8%, mainly in the posterior circulation, and found that vertebrobasilar stroke was often accompanied by arteritic anterior ischemic optic neuropathy (Gonzalez-Gay et al., 2009). This study determined the prevalence of posterior intracranial vasculitis in a largeGiant cell arteritis (GCA) is the most common primary vasculitis affecting the elderly population. GCA preferentially involves the extracranial branches of the carotid artery with sparing of intracranial vessels (Wilkinson and Russell, 1972). Occlusive vasculitis or embolization of inflammatory thrombus can result in ischemic stroke, found in approximately 2-4% of GCA patients. One series reported an incidence of 2.8%, mainly in the posterior circulation, and found that vertebrobasilar stroke was often accompanied by arteritic anterior ischemic optic neuropathy (Gonzalez-Gay et al., 2009). This study determined the prevalence of posterior intracranial vasculitis in a largeGiant cell arteritis (GCA) is the most common primary vasculitis affecting the elderly population. GCA preferentially involves the extracranial branches of the carotid artery with sparing of intracranial vessels (Wilkinson and Russell, 1972). Occlusive vasculitis or embolization of inflammatory thrombus can result in ischemic stroke, found in approximately 2-4% of GCA patients. One series reported an incidence of 2.8%, mainly in the posterior circulation, and found that vertebrobasilar stroke was often accompanied by arteritic anterior ischemic optic neuropathy (Gonzalez-Gay et al., 2009). This study determined the prevalence of posterior intracranial vasculitis in a largeGiant cell arteritis (GCA) is the most common primary vasculitis affecting the elderly population. GCA preferentially involves the extracranial branches of the carotid artery with sparing of intracranial vessels (Wilkinson and Russell, 1972). Occlusive vasculitis or embolization of inflammatory thrombus can result in ischemic stroke, found in approximately 2-4% of GCA patients. One series reported an incidence of 2.8%, mainly in the posterior circulation, and found that vertebrobasilar stroke was often accompanied by arteritic anterior ischemic optic neuropathy (Gonzalez-Gay et al., 2009). This study determined the prevalence of posterior intracranial vasculitis in a large series of patients with GCA undergoing contrast-enhanced MRI focused on intra- and extracranial vessels

Pembuatan Minuman Segar Ginger Boba

Karya Rekaman Vide

Pembuatan Natural Jelly

Karya Rekaman Vide

Pembuatan Tepung Pisang

Karya Rekaman Vide

Desa Ketapanrame Meets Desa Ranupani

Video ini berisikan tentang kegiatan para penggiat desa Wisata dan BUMDesa Ketapanrame di Desa Ranupani. Kegiatan ini merupakan benchmarking dan observasi untuk menggali informasi tentang keberhasilan Desa Ranupani menjadi Desa Wisata terbaik seluruh Indonesia untuk kategori Pengelolaan Homestay terbaik, suatu lomba yang digelar oleh Kementerian Pariwisata dan Ekonomi Kreatif/Badan Pariwisata dan Ekonomi Kreatif Republik Indonesia

Festival Kopi Padang Bulan 2021

Video ini berisikan tentang kegiatan para penggiat desa Wisata, BUMDesa Ketapanrame dan Masyarakat Desa Ketapanrame menggelar Festival Kopi Padang Bulan pada bulan November 2021. Festival ini merupakan salah satu kegiatan budaya yang diperkenalkan oleh masyarakat Ketapanrame kepada masyarakat luas. Kegiatan-kegiatan yang tergabung dalam festival kopi Padang Bulan ini terdiri dari atraksi seni budaya Bantengan, malam ramah tamah cangkrukan sambil menikmati alunan music karawitan dan seduhan kopi Banggoel, sebuah produk kopi unggulan Desa Ketapanrame